Eko Health Inc.

History

Founding and early development (2013–2017)

• 2013 – Founded at the University of California, Berkeley by Connor Landgraf, Jason Bellet, and Tyler Crouch.
• 2015 – Received FDA 510 clearance for the Eko Electronic Stethoscope System . The device was also included on TIME magazine's Best Inventions list.
• 2017 – Received FDA 510 clearance for the Eko DUO™ ECG + Digital Stethoscope .

  AI research and growth (2018–2022)

• 2018 – The FDA granted Breakthrough Device designation to Eko’s low ejection fraction algorithm developed with Mayo Clinic.
• 2020 – Received FDA clearance for AI software to detect atrial fibrillation and heart murmurs.
• 2020 – Entered into collaboration with 3M™ Littmann® to co-develop a digital stethoscope line.
• 2022 – The Lancet Digital Health published results showing that an ECG-enabled digital stethoscope with AI could identify patients with reduced ejection fraction in UK primary care.

  Product expansion and global deployment (2023–present)

• 2023 – Received FDA 510 clearances for the CORE 500® digital stethoscope family.
• 2023 – Journal of the American Heart Association published findings that a deep-learning murmur detection algorithm matched or exceeded expert performance on structural heart disease cases.
• 2023 – Research presented at the American Heart Association Scientific Sessions and published as an abstract in Circulation reported that AI-enabled digital stethoscope screening in primary care more than doubled sensitivity for detecting valvular heart disease compared with standard auscultation.
• 2023 – Partnered with Astellas Pharma to incorporate the CORE 500® Digital Stethoscope into Z1608, a solution under development for heart failure patients built on Welldoc's digital therapeutic platform.
• 2023 – Partnered with healthcare apparel company FIGS to launch the FIGS | Eko CORE 500® Digital Stethoscope, which combined Eko’s FDA-cleared CORE 500® technology with FIGS’ design elements.
• 2024 – Nature Medicine published results of a randomized trial in Nigeria showing that AI-guided screening in pregnancy more than doubled detection of left-ventricular systolic dysfunction compared with usual care.
• 2024–2025 – The American Medical Association issued a Category III CPT code for Eko’s SENSORA® platform in 2024, and the Centers for Medicare & Medicaid Services subsequently assigned an OPPS payment in 2025.
• 2025 – JACC: Advances published a large cohort validation showing that combining single-lead ECG and heart-sound data from a digital stethoscope enabled automated detection of reduced ejection fraction.
• 2025 – Formed a strategic collaboration with Boehringer Ingelheim to develop a canine-specific AI detection algorithm for the early diagnosis of heart murmurs in dogs.
• 2025 – Included in TIME magazine’s list of the World’s Top HealthTech Companies, highlighting performance and innovation in intelligent stethoscopes and AI platforms.
• 2025 – Jerome Adams, former U.S. Surgeon General, joined Eko as a Distinguished Medical Advisor to provide guidance on clinical implementation, product development, and public health partnerships.
• 2025 – Imperial College London and Imperial College Healthcare NHS Trust reported higher diagnosis rates of heart failure, atrial fibrillation, and valve disease within a 15-second exam using Eko’s AI stethoscope; results were covered in The Guardian and by the British Heart Foundation.

  Products

• CORE™ – Digital stethoscope attachment; FDA 510 K151319.
• DUO™ ECG + Digital Stethoscope – Digital stethoscope with single-lead ECG; FDA 510 K170874.
• 3M™ Littmann® CORE – Co-branded digital stethoscope using Eko’s digital platform.
• CORE 500® – Digital stethoscope with onboard display and ECG; FDA 510 K230111 and variant K233609.
• SENSORA® – AI software platform for murmur, atrial fibrillation, and reduced ejection fraction detection; received CPT Category III status in 2024 and CMS OPPS payment in 2025.

  Research and clinical validation

• Nature Medicine : A randomized trial in pregnant women found that AI-guided stethoscope screening more than doubled detection of left-ventricular systolic dysfunction compared with usual care.
• The Lancet Digital Health : A prospective UK study showed that an ECG-enabled digital stethoscope paired with an AI algorithm could screen for reduced ejection fraction in general practice settings.
• Journal of the American Heart Association : A deep-learning murmur detection algorithm matched or exceeded clinician accuracy in diagnosing structural heart disease from auscultation recordings.
• Circulation : Research presented at the American Heart Association Scientific Sessions and published as an abstract in Circulation reported that AI-enabled digital stethoscope screening in primary care more than doubled sensitivity for detecting valvular heart disease compared with standard auscultation.
• Telemedicine and e-Health : A randomized controlled trial at a National Cancer Institute–designated cancer center found that remote pre-anesthesia evaluations using an Eko Duo stethoscope achieved high concordance with in-person exams, reduced visit time and costs, and showed environmental benefits without compromising safety.
• JACC: Advances : A large cohort validation demonstrated that combining single-lead ECG and heart-sound data from a digital stethoscope enabled automated detection of reduced ejection fraction, supporting its use as an early screening tool.

  Funding

• 2018 – Raised $5 million in Series A funding led by ARTIS Ventures.
• 2019 – Raised $20 million in Series B funding, led by ARTIS Ventures.
• 2020 – Raised $65 million in Series C funding led by Highland Capital Partners and Questa Capital.
• 2022 – Raised $30 million as an extension of its Series C round.
• 2024 – Raised $41 million in Series D financing with participation from ARTIS Ventures, Highland Capital Partners, NTTVC, and Questa Capital.